Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11
NCT06440187
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
38
Enrollment
OTHER
Sponsor class
Conditions
Recurrent or Metastatic Nasopharyngeal Carcinom
Interventions
DRUG:
Gemcitabine+ nivolumab
Sponsor
Seoul National University Hospital